AIMS/HYPOTHESIS: Hyperglycaemia and dyslipidaemia are common metabolic abnormalities in adults with type 1 diabetes and both increase cardiovascular disease (CVD) risk. The hypothesis of this study was that change in HbA(1c) over 6 years would be associated with change in fasting lipids in adults with type 1 diabetes. METHODS: The Coronary Artery Calcification in Type 1 Diabetes (CACTI) study examined 652 patients with type 1 diabetes (54% female); 559 and 543 had follow-up visits at 3 and 6 years. Baseline age (mean ± SD) was 37 ± 9 years, diabetes duration 23 ± 9 years, and HbA(1c) 8.0 ± 1.3%. Use of dyslipidaemia medication was 17%, 32%, and 46% at the three visits. Separate longitudinal mixed models were fitted to examine the relationship between change in HbA(1c) and change in fasting total cholesterol (TC), HDL-cholesterol (HDL-c), LDL-cholesterol (LDL-c), log triacylglycerols (TG), and non-HDL-cholesterol (non-HDL-c). Because of an interaction between dyslipidaemia medication use and association of HbA(1c) with lipids, results were stratified by dyslipidaemia medication use. RESULTS: Among patients not using dyslipidaemia medication, a higher HbA(1c) was associated with significantly worse levels of the lipids TC, LDL-c, TG and non-HDL-c (per 1% change in HbA1c, TC 0.101 mmol/l, 95% CI 0.050, 0.152; LDL-c 0.103 mmol/l, 95% CI 0.058, 0.148; TG 0.052 mmol/l, 95% CI 0.024, 0.081; and non-HDL-c 0.129 mmol/l, 95% CI 0.078, 0.180) but not HDL-c (-0.20 mmol/l, 95% CI -0.047, 0.007). The associations between HbA(1c) and any lipid outcome among those on dyslipidaemia medication were in the same direction, but attenuated compared with persons not on medication. CONCLUSIONS/ INTERPRETATION: Change in HbA(1c) is significantly associated with change in fasting lipids, but dyslipidaemia medications may be required to optimise lipid and cardiovascular health.
AIMS/HYPOTHESIS: Hyperglycaemia and dyslipidaemia are common metabolic abnormalities in adults with type 1 diabetes and both increase cardiovascular disease (CVD) risk. The hypothesis of this study was that change in HbA(1c) over 6 years would be associated with change in fasting lipids in adults with type 1 diabetes. METHODS: The Coronary Artery Calcification in Type 1 Diabetes (CACTI) study examined 652 patients with type 1 diabetes (54% female); 559 and 543 had follow-up visits at 3 and 6 years. Baseline age (mean ± SD) was 37 ± 9 years, diabetes duration 23 ± 9 years, and HbA(1c) 8.0 ± 1.3%. Use of dyslipidaemia medication was 17%, 32%, and 46% at the three visits. Separate longitudinal mixed models were fitted to examine the relationship between change in HbA(1c) and change in fasting total cholesterol (TC), HDL-cholesterol (HDL-c), LDL-cholesterol (LDL-c), log triacylglycerols (TG), and non-HDL-cholesterol (non-HDL-c). Because of an interaction between dyslipidaemia medication use and association of HbA(1c) with lipids, results were stratified by dyslipidaemia medication use. RESULTS: Among patients not using dyslipidaemia medication, a higher HbA(1c) was associated with significantly worse levels of the lipidsTC, LDL-c, TG and non-HDL-c (per 1% change in HbA1c, TC 0.101 mmol/l, 95% CI 0.050, 0.152; LDL-c 0.103 mmol/l, 95% CI 0.058, 0.148; TG 0.052 mmol/l, 95% CI 0.024, 0.081; and non-HDL-c 0.129 mmol/l, 95% CI 0.078, 0.180) but not HDL-c (-0.20 mmol/l, 95% CI -0.047, 0.007). The associations between HbA(1c) and any lipid outcome among those on dyslipidaemia medication were in the same direction, but attenuated compared with persons not on medication. CONCLUSIONS/ INTERPRETATION: Change in HbA(1c) is significantly associated with change in fasting lipids, but dyslipidaemia medications may be required to optimise lipid and cardiovascular health.
Authors: David M Maahs; Gregory L Kinney; Paul Wadwa; Janet K Snell-Bergeon; Dana Dabelea; John Hokanson; James Ehrlich; Satish Garg; Robert H Eckel; Marian J Rewers Journal: Diabetes Care Date: 2005-02 Impact factor: 19.112
Authors: R Paul Wadwa; Gregory L Kinney; David M Maahs; Janet Snell-Bergeon; John E Hokanson; Satish K Garg; Robert H Eckel; Marian Rewers Journal: Diabetes Care Date: 2005-05 Impact factor: 19.112
Authors: Janet K Snell-Bergeon; John E Hokanson; Lisa Jensen; Todd MacKenzie; Gregory Kinney; Dana Dabelea; Robert H Eckel; James Ehrlich; Satish Garg; Marian Rewers Journal: Diabetes Care Date: 2003-10 Impact factor: 19.112
Authors: J Q Purnell; S M Marcovina; J E Hokanson; H Kennedy; P A Cleary; M W Steffes; J D Brunzell Journal: Diabetes Date: 1995-10 Impact factor: 9.461
Authors: S P Laing; A J Swerdlow; S D Slater; A C Burden; A Morris; N R Waugh; W Gatling; P J Bingley; C C Patterson Journal: Diabetologia Date: 2003-05-28 Impact factor: 10.122
Authors: Guy De Backer; Ettore Ambrosioni; Knut Borch-Johnsen; Carlos Brotons; Renata Cifkova; Jean Dallongeville; Shah Ebrahim; Ole Faergeman; Ian Graham; Giuseppe Mancia; Volkert Manger Cats; Kristina Orth-Gomér; Joep Perk; Kalevi Pyörälä; José L Rodicio; Susana Sans; Vedat Sansoy; Udo Sechtem; Sigmund Silber; Troels Thomsen; David Wood Journal: Eur Heart J Date: 2003-09 Impact factor: 29.983
Authors: Melanie Cree-Green; David M Maahs; Annie Ferland; John E Hokanson; Hong Wang; Laura Pyle; Gregory L Kinney; Martina King; Robert H Eckel; Kristen J Nadeau Journal: Pediatr Diabetes Date: 2015-06-17 Impact factor: 4.866
Authors: David M Maahs; Dana Dabelea; Ralph B D'Agostino; Jeannette S Andrews; Amy S Shah; Nancy Crimmins; Elizabeth J Mayer-Davis; Santica Marcovina; Giuseppina Imperatore; R Paul Wadwa; Steven R Daniels; Kristi Reynolds; Richard F Hamman; Lawrence M Dolan Journal: J Pediatr Date: 2012-07-11 Impact factor: 4.406
Authors: Ananta Addala; Daria Igudesman; Anna R Kahkoska; Franklin R Muntis; Katherine J Souris; Keri J Whitaker; Richard E Pratley; Elizabeth Mayer-Davis Journal: Pediatr Diabetes Date: 2019-08-15 Impact factor: 3.409